- Home
- BOLD vs NEPH Comparison
BOLD vs NEPH Comparison
Compare BOLD & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- NEPH
- Stock Information
- Founded
- BOLD 2018
- NEPH 1997
- Country
- BOLD United States
- NEPH United States
- Employees
- BOLD N/A
- NEPH N/A
- Industry
- BOLD
- NEPH Medical/Dental Instruments
- Sector
- BOLD
- NEPH Health Care
- Exchange
- BOLD Nasdaq
- NEPH Nasdaq
- Market Cap
- BOLD 30.3M
- NEPH 36.1M
- IPO Year
- BOLD 2024
- NEPH 2004
- Fundamental
- Price
- BOLD $1.07
- NEPH $4.03
- Analyst Decision
- BOLD Buy
- NEPH Buy
- Analyst Count
- BOLD 3
- NEPH 1
- Target Price
- BOLD $4.00
- NEPH $5.00
- AVG Volume (30 Days)
- BOLD 363.5K
- NEPH 67.9K
- Earning Date
- BOLD 08-11-2025
- NEPH 08-07-2025
- Dividend Yield
- BOLD N/A
- NEPH N/A
- EPS Growth
- BOLD N/A
- NEPH N/A
- EPS
- BOLD N/A
- NEPH 0.08
- Revenue
- BOLD N/A
- NEPH $15,517,000.00
- Revenue This Year
- BOLD N/A
- NEPH $17.06
- Revenue Next Year
- BOLD N/A
- NEPH $12.20
- P/E Ratio
- BOLD N/A
- NEPH $53.08
- Revenue Growth
- BOLD N/A
- NEPH 10.34
- 52 Week Low
- BOLD $1.00
- NEPH $1.36
- 52 Week High
- BOLD $4.72
- NEPH $5.00
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- NEPH 56.63
- Support Level
- BOLD N/A
- NEPH $3.83
- Resistance Level
- BOLD N/A
- NEPH $4.39
- Average True Range (ATR)
- BOLD 0.00
- NEPH 0.47
- MACD
- BOLD 0.00
- NEPH -0.07
- Stochastic Oscillator
- BOLD 0.00
- NEPH 43.27
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.